Jun 12 |
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
|
Jun 12 |
Avidity gains on early Phase 1/2 data for muscle disorder therapy
|
Jun 12 |
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
|
Jun 12 |
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
|
May 29 |
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
|
May 29 |
2 Potentially High-Reward Growth Stocks to Buy Right Now
|
May 23 |
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
|
May 19 |
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
|
May 19 |
Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
|
May 15 |
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
|